|
Iranian Journal of Pediatrics
Tehran University of Medical Sciences Press
ISSN: 1018-4406 EISSN: 2008-2150
Vol. 18, Num. 1, 2008, pp. 79-82
|
Iranian Journal of Pediatrics, Vol. 18, No. 1, March, 2008, pp. 79-82
Case Report
Enoxaparin Plus Ticlopidine: An Effective Combination Therapy
for Intracardiac Thrombi in Thalassemia Intermedia
Mohammad Saeed Rahiminejad*1, MD, Pediatric Hematologist; Mohammad Bagher Sharifkazemi 2, MD, Cardiologist;Kambiz Sotoudeh3, General Physician
1Department of Pediatrics, Tehran University of Medical Sciences, IR Iran
2Department of
Cardiology, Shiraz University of Medical Sciences, IR Iran
3Research Development Center, Tehran University of Medical Sciences,IR Iran
* Correspondence author;
Address: Hematology Devision, Children’s Medical Center, Dr Gharib Ave, Tehran, IR Iran.
E-mail: rahiminms@hotmail.com
Received: 02/06/07; Accepted: 17/12/07
Code Number: pe08014
Abstract
Objective: Patients with thalassemia intermedia have an increased
risk of thrombotic events as compared to the general population.
Case Presentation: We
describe two cases of thalassemia intermedia with intracardiac thrombi who
failed to response to traditional anticoagulation therapy with Unfractionated
Heparin and Aspirin; but thrombolysis occurred following combination therapy
with Ticlopidine and Enoxaparin.
Conclusion: Our
experience in patients shown combination of Enoxaparin and Ticlopidine is
effective for treatment of ventricular thrombus in TI patients.
Key Words:Thalassemia intermedia,
Intracardiac Thrombus, Enoxaparin, Ticlopidine
Introduction
Thalassemia intermedia (TI) patients arecharacterized by a transfusion independent course of
intermediate severity between beta-thalassemia major and asymptomatic carriers[1].
Increased tendency of thrombosis has been reported in thalassemia patients
suggesting a hypercoagulable state can be present in thalassemia syndromes[2].
In a recent study 4% of 2190 patients with thalassemia intermedia and 0.9% of
6670 patients with thalassemia major experienced a thrombotic event[3].
Recommended treatments in these settings are aspirin and/or low molecular
weight heparin (LMWH)[3]. In this paper we have reported two cases
of thalassemia intermedia with potentially life threatening heart thrombi in
which anticoagulation therapy with aspirin and low molecular weight heparin failed
but thrombi disappeared after Ticlopidine was added to LMWH in a short time.
Case Presentation
Case 1: A 26-year-old female, a diagnosed
case of thalassemia intermedia, was admitted in July 2003 with a one day
history of chest pain. After a general physical examination and complete
paraclinical tests, a pea size thrombus attached to the apex was found by
transthoracic echocardiography, indicating
it was probably of local origin. In echocardiography, global left ventricle
hypokinesia, trivial mitral valve insufficiency, normal pulmonary artery
pressure and ejection fraction of 30% also were found. In electrocardiogram a sinus
tachycardia was present.
She
regularly received one unit packed red blood cell every two months and had no
history of thrombotic events. She was splenectomized. Renal and liver function
tests as well as serum glucose, cholesterol and triglyceride levels were
normal. Prothrombin time, activated partial thromboplastin time, bleeding time,
serum fibrinogen, protein S, protein C, factor V and VII were in normal range. Hemoglobin
at admission was 8.5 g/dL. Blood cultures were negative for several times. She
also denied using any drugs except for iron chelating agents (Deferoxamine)
five days a week.
Intravenous infusion of Standard Unfractionated
Heparin (UFH) was started intravenously with a dose of 18000 Unit/day, but
despite adequate dosage (PTT increased to 1.5 × normal) echocardiography showed
an increase in the size of thrombus after 3 days. Aspirin (80 mg/day, oral) was
added but severe epistaxis developed, therefore both drugs were discontinued
and Enoxaparin (low molecular weight heparin) was started subcutaneously with a
dose of 40 mg/day. After two days the size of thrombus was not changed and a
new fresh and small thrombus was detected in the right ventricles apex. Evaluation
of calf and pelvic veins for source of the thrombosis was not significant.
Ticlopidine (250 mg/every 12 hours, oral) was added to Enoxaparin, thereupon
the size of thrombi started to decrease and two weeks later no thrombus could
be detected by echocardiography. This combination therapy continued
(Ticlopidine for two months and Enoxaparin for six months). In follow up study
after one, two and six months there was no evidence of thrombus in the heart.
She visited us in late august 2006 and her heart was clear.
Case 2: In November 2003 a 28-year-old man
was admitted for his cardiomyopathy and biventricular heart failure. He was a
case of thalassemia intermedia with regular transfusions every 15 days. Four months
before admission he underwent splenectomy because of hypersplenism. In
admission he had hepatomegaly, moderate pleural effusion, moderate ascites and
2+ pitting edema in lower extremities, increased jugular vein
pressure with hemoglobin 8.4 g/dL and platelet count 34000/μL. Total and
direct bilirubins were 6.2 and 2.3 mg/dL, respectively. Prothrombin time was 22
sec (control 12 sec) and activated partial thromboplastin time 120 sec (control
35 sec).
Blood culture in several occasions was negative.
In electrocardiogram, right bundle branch block, right axis deviation and right
ventricular hypertrophy and tachycardia were seen. Echocardiography showed
dilated chambers with a globular thrombus (2 cm2), mild mitral
regurgitation and global hypokinesia. Color Doppler sonography of lower limbs
was normal. The patients present underlying cardiac disease was too risky for
surgical intervention, therefore nonsurgical treatment was chosen.
Standard Unfractionated Heparin (20.000 unit/day,
injected intravenously) was started. 3 days later an increased size of thrombus
was demonstrated in echocardiography. The treatment has been changed to
Enoxaparin plus Ticlopidine (250 mg/every 12 hours, oral). After 10 days the
size of thrombus decreased to one third. Patient died after two weeks due to
his cardiomyopathy and hepatic insufficiency.
Discussion
Thalassemia intermedia patients similar to the
thalassemia major patients, predispose to thrombotic events[2,4]. In
thalassemia intermedia patients, these events primarily occurred in the venous
system and comprised deep vein thrombosis, portal vein thrombosis, stroke,
pulmonary embolism and other symptoms[2-4]. Moreover; the risk of
thrombosis in splenectomized TI patients is more than in non-splenectomized TI
patients[2,4]. Although the pathogenesis is uncertain, thrombophilic
state in TI patients is attributed to the procoagulant activity of damaged red
blood cells (RBC) and the abnormal exposure of phosphatidyl-serin from the RBC
remnants. Other hypothesized mechanisms include coinheritance of coagulation
defects, endothelial inflammation, depletion of antithrombotic factors, and
stressful conditions that increase thrombosis formation[2,3].
Spontaneous intracardiac thrombus in the absence of any
predisposing cardiac disease that was seen in case one, is a rare event,
because the main causes of left ventricular thrombi, namely acute myocardial
infarction and dilated cardiomyopathy, were not seen in that patient[5].
On the other hand biventricular thrombi in case 1 was an even more rare
condition and have been reported to occur in patients with dilated
cardiomyopathy, ischemic cardiomyopathy and hypercoagulable state secondary to
nephrotic syndrome[6]. Despite left ventricular thrombi, thrombi in the
right ventricle may develop within the right heart chambers or may be
peripheral venous clots that on their way to the lungs, accidentally lodge in
right ventricle[7].
There is no consensus regarding the optimal
treatment of ventricular thrombi. Over the past 30 years, the primary
therapeutic options have included surgical removal of thrombi, anticoagulation,
or more recently, thrombolysis. Some cases of intravenous thrombolysis have
been reported, but risks of bleeding and embolism were too high[8]. Similarly
the use of tissue plasminogen activator (t-PA) for cardiac thrombus is
controversial because it could potentially accelerate break up of the thrombus
and cause additional embolies. Some authors have been advocating a surgical
approach for patients with mobile and pedunculated thrombi, but such patients
are exposed to a high risk of complications of surgery[9]. The most
common therapeutic approach consists in the administration of intravenous UFH
followed by oral anticoagulation therapy[5]. Although in many
conditions efficacy of LMWHs are equivalent or superior to UFH, UFH has been
considered as the treatment of choice for left ventricle thrombus[5,10].
LMWH for treatment of left ventricular thrombi
was not evaluated before and only one clinical case was reported[11].
Recently a preliminary study showed the safety and efficacy of LMWH
(Enoxaparin) in disappearance or size reduction of left ventricular thrombi
associated with acute myocardial infarction or dilated cardiomyopathy. Aspirin
and Clopidogrel in combination with LMWH were used in that study but neither
the etiology of cardiac problem nor the different antiaggregant treatments
appeared to influence the progression of thrombi on LMWH therapy[5].
In this country Ticlopidine has been available
for several years, however its use has been limited by the significant risk of
neutropenia[12]. Ticlopidine inhibits the binding of adenosine 5'-
diphosphate (ADP) to its platelet receptor and this ADP receptor blockade leads
to direct inhibition of fibrinogen binding to the glycoprotein IIa/IIIb
complex. Also Ticlopidine may interfere with von Willebrand factor, resulting
in less binding of von Willebrand factor to platelet receptors[13].
In our cases, when we added Ticlopidine to
LMWH, thrombolysis potency increased and it is suggested that this combination
therapy may be more potent than each of them.The mechanism of this
additive thrombolysis is not well known. However, it may be due to at least two
mechanisms: One is that, addition of Ticlopidine to LMWH improves the antiplatelet
activity and leads to dissolving of thrombus in a process similar to
dethrombosis[14,15]. The second one is a particularly thrombolytic
action of those drugs in TI patients with an unknown mechanism.
Conclusion
Although our experience is limited to the treatment
of two patients, we believe that combination of Enoxaparin and Ticlopidine is
effective for treatment of ventricular thrombus in TI patients. Whether this
combination therapy is specific for TI patients or not, should be further evaluated
with more patients.
References
- Camaschella C,
Capellini MD. Thalassemia intermedia. Haematologica. 1995;80(1): 58-68.
-
Taher A,
Isma'eel H, Capellini MD. Thalassemia intermedia: Revisited. Blood Cells Mol Dis.
2006;37(1):12-20.
- Eldor A,
Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99(1):36-43.
- Capellini MD,
Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability
in splenectomized patients with thalassemia intermedia. Br J Haematol.
2000;111(2):467-73.
- Meurin
P, Tabet JY, Renaud N, et al. Treatment of left ventricular thrombi with a low molecular weight
heparin. Int J Cardiol. 2005;98(2):319-23.
-
Wongpraparut
N, Apiyasavat S, Jacobs LE. Biventricular thrombi. Echocardiography 2001;18(7):619-20.
- Rose P,
Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest. 2002; 121(3):806-14.
- Van
Dantzig JM, Delamarre J, Bot H, et al. Left ventricular thrombus in acute myocardial infarction.
Eur Heart J. 1996; 17(11):1640-5.
-
Nili
M, Deviri E, Jortner R, et al. Surgical removal of a mobile pedunculated left ventricular thrombus:
report of 4 cases. Ann Thorac Surg. 1988;46(4):396-400.
- Heik
SC, Kupper W, Hamm C, et al. Efficacy of high dose intravenous heparin for treatment of left
ventricular thrombi with high embolic risk. J Am Coll Cardiol. 1994; 24(5):1305-9.
-
Mallory R,
Balcezac T. Treatment of a mobile left ventricular thrombus with low molecular
weight heparin. Letter to editor. N Engl J Med. 1999;341(14):1082-3.
- Sharis PJ,
Cannon CP, Loscalzo J. The antiplatelet effects of Ticlopidine and Clopidegrol.
Ann Intern Med. 1998; 129(5):394-405.
- Di Minno G,
Cerbone AM, Mattioli PL, et al. Functionally thrombasthenic state in normal
platelets following the administration of ticlopidine. J Clin Invest. 1985;75(2):328-38.
-
Muhlestein JB.
Fibrin-fibrinogen and dethrombosis. Blood Coag Fibrinolysis. 1999;10(Suppl
1):S59.
- Luciardi H,
Berman S, Muntaner J, et al. Facilitated Thrombolysis: Dethrombosis? Clin Appl
Thrombosis/Hemostasis. 2002; 8(2):133-8.
© Copyright 2008 - TUMS PUBLICATIONS
|